OncoMatch/Clinical Trials/NCT06163430
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Official title: A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia
Is NCT06163430 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies MK-4208 for leukemia, myelogenous, chronic, bcr-abl positive.
Treatment: MK-4208 — Researchers are looking for a new way to treat a blood cancer called chronic myeloid leukemia (CML). Researchers want to learn if MK-4208 (Tern-701) can treat this type of blood cancer. The goal of this study is to learn about the safety of different doses (amounts) of MK-4208 (Tern-701) and if people tolerate them. Researchers also want to find the highest dose of MK-4208 (Tern-701) that people can tolerate and may work to treat blood cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Chronic Myeloid Leukemia
Biomarker criteria
Required: ABL1 bcr-abl1 fusion
Disease stage
Required: Stage CHRONIC PHASE
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: tyrosine kinase inhibitor
Have received treatment with at least one prior tyrosine kinase inhibitor (TKI) and have treatment failure, suboptimal response, or treatment intolerance
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama Medicine (UAB Medicine) · Birmingham, Alabama
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- UC Irvine Health · Orange, California
- Rocky Mountain Cancer Centers, LLP · Lone Tree, Colorado
- Florida Cancer Specialists - South Region Research Office · Fort Myers, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06163430 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received tyrosine kinase inhibitor.
Does this trial require ABL1?
Yes, ABL1 bcr-abl1 fusion is a required biomarker for enrollment.
What disease stage is eligible?
Stage CHRONIC PHASE is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify